Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.85 HKD | -5.85% | -5.14% | +40.03% |
Apr. 30 | Giant Biogene’s Profit Up 47% in 2023 | MT |
Mar. 26 | Giant Biogene to Pay Special 0.45 Yuan per Share Dividend | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The firm trades with high earnings multiples: 25.39 times its 2024 earnings per share.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+40.03% | 6.24B | - | ||
+13.58% | 143B | B- | ||
+18.09% | 77.23B | A+ | ||
-12.61% | 65.42B | A- | ||
-7.86% | 48.32B | B+ | ||
-4.92% | 39.2B | - | ||
+6.63% | 35.21B | B- | ||
+11.64% | 18.31B | A- | ||
+14.87% | 15.9B | B | ||
-3.09% | 11.4B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2367 Stock
- Ratings Giant Biogene Holding Co., Ltd.